S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL by Arnon Kater, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit Veldhuis, Rogier Mous, Clemens Mellink, Johan Dobber, Christian Poulsen, Caspar Da Cunha-Bang, Hendrik Fredriksen, Ann Janssens, Ida Schjodt, Ellen Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Mark-David Levin, Carsten Niemann

Get full text